Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects.
Loading...
Issue Date
2021
Authors
Bettinger, Jeffrey
Batista Quevedo, Himayapsill
Cleary, Jacqueline H
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Buprenorphine's unique pharmacologic mechanisms of action lend itself to a higher level of complexity than its typical characterization as a partial agonist at µ-opioid receptors. It is well-documented that its additional activity at Δ- and κ-opioid receptors, and opioid receptor ligand 1 may be associated with varying degrees of analgesia and usual opioid-related adverse effects. However, novel downstream molecular and cellular mechanisms from µ-opioid receptor activation contain potential new insights into its overall unique effects. These include buprenorphine's peculiar ability to induce analgesia at escalating doses, while exhibiting a plateaued effect on respiratory depression, euphoria, gastrointestinal (GI) motility, depression, anxiety, and addictive potential. Thus, this review aims to discuss several of these emerging mechanisms to gain a better understanding of these curious actions, as well as support much of this in vitro evidence with various human clinical trial data to further support buprenorphine's place on the analgesic ladder.
Citation
Bettinger J, Batista Quevedo H, Cleary J. Emerging pharmacologic mechanisms of buprenorphine to explain experience of analgesia versus adverse effects. J Opioid Manag. 2021;17(7):21-31. doi: 10.5055/jom.2021.0639. PMID: 34520023.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).